EHD1, CPTAC-68 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

10 20 30 40 50
MFSWVSKDAR RKKEPELFQT VAEGLRQLYA QKLLPLEEHY RFHEFHSPAL
60 70 80 90 100
EDADFDNKPM VLLVGQYSTG KTTFIRHLIE QDFPGMRIGP EPTTDSFIAV
110 120 130 140 150
MHGPTEGVVP GNALVVDPRR PFRKLNAFGN AFLNRFMCAQ LPNPVLDSIS
160 170 180 190 200
IIDTPGILSG EKQRISRGYD FAAVLEWFAE RVDRIILLFD AHKLDISDEF
210 220 230 240 250
SEVIKALKNH EDKIRVVLNK ADQIETQQLM RVYGALMWSL GKIINTPEVV
260 270 280 290 300
RVYIGSFWSH PLLIPDNRKL FEAEEQDLFK DIQSLPRNAA LRKLNDLIKR
310 320 330 340 350
ARLAKVHAYI ISSLKKEMPN VFGKESKKKE LVNNLGEIYQ KIEREHQISP
360 370 380 390 400
GDFPSLRKMQ ELLQTQDFSK FQALKPKLLD TVDDMLANDI ARLMVMVRQE
410 420 430 440 450
ESLMPSQVVK GGAFDGTMNG PFGHGYGEGA GEGIDDVEWV VGKDKPTYDE
460 470 480 490 500
IFYTLSPVNG KITGANAKKE MVKSKLPNTV LGKIWKLADV DKDGLLDDEE
510 520 530 534
FALANHLIKV KLEGHELPAD LPPHLVPPSK RRHE

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for CPTAC-69 Collapse assay details

Data source: Panorama

Official Gene Symbol

EHD1

Peptide Sequence

ELVNNLGEIYQK

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

330

Peptide End

341

CPTAC ID

CPTAC-69

Peptide Molecular Mass

1,418.7405

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Fred Hutchinson Cancer Research Center

Submitting Lab PI

Amanda Paulovich


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y9 (1+) | 22.2 | 12 | 9.4 | 28.9 | 12.2 | 10.8 | 36.4 | 17.1 | 14.3 | 15 | 25 | 15 | | y7 (1+) | 24.2 | 14.6 | 5.3 | 24.6 | 13.5 | 8.9 | 34.5 | 19.9 | 10.4 | 15 | 25 | 15 | | y6 (1+) | 16.7 | 6.7 | 10.7 | 20.1 | 8.2 | 10.1 | 26.1 | 10.6 | 14.7 | 15 | 25 | 15 | | sum | 11.7 | 6.6 | 5.9 | 18.1 | 8.1 | 6.8 | 21.6 | 10.4 | 9 | 15 | 25 | 15 |



Additional Resources and Comments


Assay Details for CPTAC-68 Collapse assay details

Data source: Panorama

Official Gene Symbol

EHD1

Peptide Sequence

LFEAEEQDLFK

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

270

Peptide End

280

CPTAC ID

CPTAC-68

Peptide Molecular Mass

1,367.6609

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Fred Hutchinson Cancer Research Center

Submitting Lab PI

Amanda Paulovich


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y9 (1+) | 29.3 | 9.3 | 8 | 82.2 | 18.7 | 12 | 87.3 | 20.9 | 14.4 | 15 | 25 | 15 | | y8 (1+) | 30.4 | 13.9 | 10.3 | 33 | 21 | 23.3 | 44.9 | 25.2 | 25.5 | 15 | 25 | 15 | | y6 (1+) | 22 | 21.8 | 22.9 | 33.2 | 22.2 | 33.5 | 39.8 | 31.1 | 40.6 | 15 | 25 | 15 | | sum | 12 | 9 | 8.6 | 19.7 | 18.6 | 17 | 23.1 | 20.7 | 19.1 | 15 | 25 | 15 |



Additional Resources and Comments